Immunoglobulin G1 [188,412-bis[4-(azidomethyl)-L-phenylalanine]], anti-(human folate receptor ?) (human-Mus musculus monoclonal SP8166 ?1-chain), disulfide with human-Mus musculus monoclonal SP8166 ?-chain, dimer, click reaction product with 3-[[[[4-[[N-[4-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-1,4-dioxobutyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-N,?,?-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl-L-valinamide (1:4)
Endometrioid Adenocarcinoma
Sutro Biopharma, Inc.antibody_drug_conjugatePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 31/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Endometrioid Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Avutometinib University of Oklahoma | Phase 2 | B |
Carboplatin National Cancer Institute (NCI) | Phase 2 | B |
Indocyanine Green Centre Oscar Lambret | Phase 3 | B |
Defactinib University of Oklahoma | Phase 2 | B |
PATENT BLUE VIOLET Centre Oscar Lambret | Phase 3 | B |
View all 28 →
Same molecule, other indications
Immunoglobulin G1 [188,412-bis[4-(azidomethyl)-L-phenylalanine]], anti-(human folate receptor ?) (human-Mus musculus monoclonal SP8166 ?1-chain), disulfide with human-Mus musculus monoclonal SP8166 ?-chain, dimer, click reaction product with 3-[[[[4-[[N-[4-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-1,4-dioxobutyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-N,?,?-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl-L-valinamide (1:4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →